AzTrials
AzTrials

Metastatic Castration-Resistant Prostate CancerPhase 3SPLASHNCT04647526

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

A Phase 3 study testing [Lu-177]-PNT2002, Abiraterone and Enzalutamide in people with Metastatic Castration-Resistant Prostate Cancer, run by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company at 54 sites in 6 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT). Read more about this study

Who is it for?
Ages 18 years and older, men only
What is being tested?
[Lu-177]-PNT2002, Abiraterone and Enzalutamide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
455 participants
Where
54 sitesin 6 countries
Study dates
25 Feb 2021to Mar 2028
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male aged 18 years or older.
  • Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate.
  • Ineligible or averse to chemotherapeutic treatment options.
  • Patients must have progressive mCRPC at the time of consent based on at least 1 of the following criteria:
  • Serum/plasma PSA progression defined as increase in PSA greater than 25% and >2 ng/mL above nadir, confirmed by progression at 2 time points at least 3 weeks apart.
  • Soft-tissue progression defined as an increase ≥20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or a new lesion.
Show all 27Show fewer
  • Progression of bone disease defined as the appearance of two or more new lesions by bone scan.
  • Progression on previous treatment with one ARAT (abiraterone or enzalutamide or darolutamide or apalutamide) in either the CSPC or CRPC setting.
  • PSMA-PET scan (i.e., 68Ga-PSMA-11 or 18F-DCFPyL) positive as determined by the sponsor's central reader.
  • Castrate circulating testosterone levels (<1.7 nmol/L or <50 ng/dL).
  • Adequate organ function, independent of transfusion:
  • Bone marrow reserve:
  • i. White blood cell (WBC) count ≥2.5 × 10^9/L OR absolute neutrophil count (ANC) ≥1.5 × 10^9/L.
  • ii. Platelets ≥100 × 10^9/L.
  • iii. Hemoglobin ≥8 mmol/L.
  • Liver function:
  • i. Total bilirubin ≤1.5 × institutional upper limit of normal (ULN). For patients with known Gilbert's syndrome, ≤3 × ULN is permitted.
  • ii. ALT or AST ≤3.0× ULN.
  • Renal function:
  • i. Serum/plasma creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min based on Cockcroft-Gault formula (for patients in France, serum/plasma creatinine ≤1.5 × ULN or CrCl ≥60 mL/min based on Cockcroft-Gault formula).
  • Albumin ≥30 g/L.
  • Human immunodeficiency virus-infected patients who are healthy and have a low risk of acquired immunodeficiency syndrome-related outcomes are included in this trial.
  • For patients who have partners who are pregnant or of childbearing potential: a condom is required along with a highly effective contraceptive method during the study and for 6 months after last study drug administration. Such methods deemed highly effective include a) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, b) progestogen-only hormonal contraception associated with inhibition of ovulation, c) intrauterine device (IUD), d) intrauterine hormone-releasing system (IUS), e) bilateral tubal occlusion, f) vasectomy, g) true sexual abstinence: when this is in line with the preferred and usual lifestyle of the subject [periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to IMP, and withdrawal are not acceptable methods of abstinence].
  • Willing to initiate ARAT therapy (either enzalutamide or abiraterone), pre-specified by investigator, if randomized to Treatment Arm B.
  • ECOG performance status 0 to 1.
  • Willing and able to comply with all study requirements and treatments (including 177Lu PNT2002) as well as the timing and nature of required assessments.
  • Signed informed consent.

Who cannot join

  • Patients are excluded from the study if any of the following criteria apply:
  • If noted in pathology report, prostate cancer with known significant (>10% present in cells) sarcomatoid or spindle cell or neuroendocrine components. Any small cell component in the cancer should result in exclusion.
  • Prior treatment for prostate cancer ≤28 days prior to randomization, with the exclusion of first-line local external beam, ARAT, luteinizing hormone-releasing hormone (LHRH) therapy, or non-radioactive bone-targeted agents.
  • Any prior cytotoxic chemotherapy for CRPC (e.g., cabazitaxel or docetaxel); chemotherapy for hormone-sensitive prostate cancer (HSPC) is allowed if the last dose was administered >1 year prior to consent.
  • Prior treatment with systemic radionuclides (e.g. radium-223, rhenium-186, strontium 89).
  • Prior immuno-therapy, except for sipuleucel-T.
Show all 26Show fewer
  • Prior PSMA-targeted radioligand therapy, e.g., Lu-177-PSMA-617, I 131-1095.
  • Prior poly ADP ribose polymerase (PARP) inhibitor for prostate cancer.
  • Patients who progressed on 2 or more lines of ARATs.
  • Patients receiving bone-targeted therapy (e.g. denosumab, zoledronic acid) not on stable doses for at least 4 weeks prior to randomization.
  • Administration of an investigational agent ≤60 days or 5 half-lives, whichever is shorter, prior to randomization.
  • Major surgery ≤30 days prior to randomization.
  • Estimated life expectancy <6 months as assessed by the principal investigator.
  • Presence of liver metastases >1 cm on abdominal imaging.
  • A superscan on bone scan defined as a bone scan that demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint genitourinary tract activity.
  • Dose escalation or initiation of opioids for cancer-related pain ≤30 days prior to consent up to and including randomization.
  • Known presence of central nervous system metastases.
  • Contraindications to the use of planned ARAT therapy, [Ga-68]-PSMA-11, [F-18]-DCFPyL or [Lu-177]-PNT2002 therapy, including but not limited to the following:
  • Hypersensitivity to [Ga-68]-PSMA-11, [F-18]-DCFPyL or [Lu-177]-PNT2002 excipients (Diethylenetriaminepentaacetic acid (DTPA), Sodium ascorbate, Lascorbic acid, Sodium gentisate, HCl, Sodium hydroxide).
  • Recent myocardial infarction or arterial thrombotic events (in the past 6 months) or unstable angina (in the past 3 months), bradycardia or left ventricular ejection fraction measurement of < 50%.
  • History of seizures in patients planned to receive enzalutamide.
  • Active malignancy other than low-grade non-muscle-invasive bladder cancer and non-melanoma skin cancer.
  • Concurrent illness that may jeopardize the patient's ability to undergo study procedures.
  • Serious psychological, familial, sociological, or geographical condition that might hamper compliance with the study protocol and follow-up schedule. Patients that travel need to be capable of repeated visits even if they are on the control arm.
  • Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
  • Concurrent serious (as determined by the investigator) medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure (see 12.1 Appendix 1), unstable ischemia, uncontrolled symptomatic arrhythmia, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation.

Trial locations and contacts

54 sites in 6 countries.

54 sites in 6 countries

United States33 sites

  • New Mexico Oncology Hematology Consultants Ltd., New Mexico Cancer Center

    Albuquerque, New Mexico, 87109

  • University of Michigan Hospitals

    Ann Arbor, Michigan, 48109

  • University of Colorado Hospital

    Aurora, Colorado, 80045

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland, 21201

  • Tri-State Urologic Services

    Cincinnati, Ohio, 45212

  • Dallas VA Medical Center, Nuclear Medicine Service

    Dallas, Texas, 75216

  • UT Southwestern Medical Center

    Dallas, Texas, 75390

  • Karmanos Cancer Center

    Detroit, Michigan, 48201

  • Astera Cancer Care

    East Brunswick, New Jersey, 08816

  • Excel Diagnostics & Nuclear Oncology Center

    Houston, Texas, 77402

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, 52242

  • Greater Dayton Cancer Center

    Kettering, Ohio, 45409

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky, 40536

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California, 90048

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California, 90073

  • University of California Los Angeles, Nuclear Medicine Clinic

    Los Angeles, California, 90095

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina, 29572

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, 37232

  • Tulane University Medical Center

    New Orleans, Louisiana, 70112

  • New York Presbyterian Hospital/Weill Cornell Medical Center

    New York, New York, 10065

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92663

  • Urology Cancer Center, PC

    Omaha, Nebraska, 68130

  • UC Irvine Chao Family Comprehensive Cancer Center

    Orange, California, 92868

  • Stanford Cancer Institute

    Palo Alto, California, 94305

  • Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania, 19104

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111

  • Swedish Cancer Institute Research

    Seattle, Washington, 98104

  • VA St. Louis Health Care System

    St Louis, Missouri, 63106

  • Saint Louis University Hospital

    St Louis, Missouri, 63110

  • Washington University School of Medicine

    St Louis, Missouri, 63110

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida, 33612

  • Chesapeake Urology Associates (CUA) P.A.

    Towson, Maryland, 21204

  • Arizona Institute of Urology (AIU) - Tucson

    Tucson, Arizona, 85704

Other trials in United States

Canada8 sites

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, B3H 2Y9

  • London Health Sciences Center - Victoria Hospital

    London, Ontario, N6A 5W9

  • CHUM - University Hospital of Montreal

    Montreal, Quebec, H2X 3E4

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2

  • CHU of Quebec - Laval University

    Québec, Quebec, G1R 2J6

  • Sunnybrook Research Institute, Odette Cancer Center

    Toronto, Ontario, M4N 3M5

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9

  • BC Cancer - Vancouver

    Vancouver, British Columbia, V5Z 4E6

Other trials in Canada

France6 sites

  • Center Jean Perrin, Department of Medical Oncology

    Clermont-Ferrand, 63011

  • Claude Huriez Hospital

    Lille, 59037

  • Leon Berard Center

    Lyon, 69373

  • La Timone Hospital, Nuclear Medicine Department

    Marseille, 13385

  • Montpellier Cancer Institute, Department of Nuclear Medicine

    Montpellier, 34298

  • Tenon Hospital, Department of Medical Oncology

    Paris, 75020

Other trials in France

Netherlands3 sites

  • St. Antonius Hospital

    Nieuwegein

  • Radboud University Medical Center (Radboudumc)

    Nijmegen

  • Erasmus University Medical Center Rotterdam

    Rotterdam, 3015 GD

Other trials in Netherlands

Sweden2 sites

  • Sahlgrenska University Hospital

    Gothenburg, 41345

  • Norrlands University Hospital, Department of Radiation Sciences, Oncology

    Umeå

Other trials in Sweden

United Kingdom2 sites

  • Charing Cross Hospital, Department of Medical Oncology

    London

  • Royal Marsden NHS Foundation Trust - Institute of Cancer Research

    Sutton

Other trials in United Kingdom

About this study

Official title: A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).

Read the detailed description

The primary objective of the study is to determine the efficacy of [Lu-177]-PNT2002 ([Lu-177]-PSMA-I\&T) versus abiraterone or enzalutamide in delaying radiographic progression in patients with mCRPC.

The study consists of 3 phases: Dosimetry, Randomized Treatment, and Long term Follow up.

The study will commence with a 25-patient safety and dosimetry lead-in (Part 1) and proceed to a randomization treatment phase in approximately 390 patients (Part 2). Patients in Part 2 will be randomized in a 2:1 ratio to receive either [Lu-177]-PNT2002 (Arm A), or enzalutamide or abiraterone (Arm B). Patients in Arm B who experience radiographic progression per central review and meet protocol defined eligibility, may crossover to receive [Lu-177]-PNT2002. After final overall survival (OS) analysis, all patients will continue to be followed through Continued Access, including long-term follow-up (LTFU) for at least 5 years from the first therapeutic dose, death, or loss to follow up (Part 3).

Only patients that meet PSMA PET avidity criteria per central review will be eligible for this study.

Being tested
[Lu-177]-PNT2002, Abiraterone, Enzalutamide
Keywords
PSMA, mCRPC, Prostate cancer, 177Lu-PSMA, radioligand therapy, PSMA-I&T, SPLASH
Medical subject headings
Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • [Lu-177]-PNT2002Drug

    Also called [Lu-177]-PSMA-I&T, LY4187525

    Participants randomized to Arm A will receive 6.8 GBq (±10%) of [Lu-177]-PNT2002 every 8 weeks for 4 cycles

  • AbirateroneDrug

    Abiraterone (1000 mg orally once daily with: 5 mg twice daily prednisone or 0.5 mg once daily dexamethasone)

  • EnzalutamideDrug

    Enzalutamide (160 mg orally once daily)

Study groups in NCT04647526
Study groupRoleWhat they receive
Lead-in Dosimetry Phase: [Lu-177]-PNT2002ExperimentalParticipants received 6.8 gigabecquerels (GBq) (±10%) of [Lu-177]-PNT2002 by intravenous infusion every 8 weeks for 4 cycles.
Receives: Drug: [Lu-177]-PNT2002
Randomization Phase: [Lu-177]-PNT2002 (Arm A)ExperimentalParticipants received 6.8 GBq (±10%) of [Lu-177]-PNT2002 by intravenous infusion every 8 weeks for 4 cycles.
Receives: Drug: [Lu-177]-PNT2002
Randomization Phase: Abiraterone or Enzalutamide (Arm B)Active comparatorParticipants received either of below treatments until radiographic progression. * Enzalutamide 160 milligram (mg) orally once daily (or) * Abiraterone 1000 mg orally once daily coadministered with prednisone 5 mg orally twice daily or dexamethasone 0.5 mg orally once daily. Participants who experienced radiographic progression per Blinded Independent Central Review (BICR) (or after final overall survival (OS), per local investigator-assessment), had not started an intervening treatment, and had no uncontrolled adverse events (AEs) were eligible to consent to cross over to receive 6.8 GBq (±10%) of [Lu-177]-PNT2002 intravenous infusion every 8 weeks for 4 cycles.
Receives: Drug: [Lu-177]-PNT2002; Drug: Abiraterone; Drug: Enzalutamide
Pharmacokinetic (PK) Extension Phase: [Lu-177]-PNT2002ExperimentalParticipants received 6.8 GBq (±10%) of [Lu-177]-PNT2002 by intravenous infusion every 8 weeks for 4 cycles.
Receives: Drug: [Lu-177]-PNT2002

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Randomization Phase: Radiographic Progression-Free Survival (rPFS)

    • rPFS, as assessed by blinded independent central review (BICR), is the time from the randomization date to progression on soft tissue per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or confirmed progression on bone lesions by Prostate Cancer Working Group 3 (PCWG3) criteria, or death from any cause.
    • The date of disease progression is the date of the scan for the first objectively documented progressive disease (PD) per RECIST v1.1 or PCWG3. PD is defined as a ≥20% increase in the sum of the diameters of target lesions (≥5 mm absolute), with reference being the smallest sum in the study, or unequivocal progression of non-target lesions, or appearance of new lesions.
    • Participants who do not progress, including those who started new anticancer therapy, withdrew from the study, or were lost to follow-up without disease progression, were censored at the last valid assessment for RECIST v1.1 or PCWG3.

    Measured: From the randomization date to the first documented progressive disease or death from any cause (up to 23 months)

Secondary outcomes (5)

  1. Randomization Phase: Percentage of Participants With Objective Response Rate (ORR)

    • ORR, as assessed by BICR, is the best confirmed overall tumor response of complete response (CR) or partial response (PR) as per RECIST v1.1 ( in the absence of confirmed progression on bone scan assessed by PCWG3).
    • CR is a disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 millimeters (mm).
    • PR is at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), without progression of non-target lesions or appearance of new lesions.

    Measured: Randomization until measured progressive disease (up to 23 months)

  2. Randomization Phase: Duration of Response

    Duration of Response, as assessed by BICR, is the time from the date of first documented confirmed CR or PR as per RECIST v1.1 (in the absence of confirmed progression on bone scan assessed by PCWG3) to the date of first documented radiographic progression or death in the absence of progression. Participants who have attained CR or PR as the best overall response, did not have progressive disease, and did not die will be censored.

    Measured: From the date of first CR or PR to disease progression or death (up to 16.3 months)

  3. Randomization Phase: Percentage of Participants With Prostate-Specific Antigen (PSA) Response Rate

    The PSA response rate, as per the PCWG3 criteria, is the percentage of participants achieving a ≥50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second PSA assessment conducted at least 3 weeks later.

    Measured: From the randomization up to 23 months

  4. Randomization Phase: Biochemical Progression-Free Survival (bPFS)

    bPFS is the time from the date of randomization to the date of the first PSA increase from baseline ≥25% and ≥2 nanograms per milliliter (ng/mL) above nadir confirmed by a second PSA measurement defining progression ≥3 weeks later, as per PCWG3, or death from any cause in the absence of progression. Participants who do not progress or die including those who withdraw from the study or are lost to follow-up will be censored at the time of last valid PSA measurement.

    Measured: From the randomization up to 23 months

  5. Overall Survival

    Time from the date of randomization until death due to any cause.

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Dec 2020
  2. Study start25 Feb 2021
  3. Primary completion1 Nov 2023
  4. Study completionMar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
455 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04647526
Sponsor's protocol ID
27232
Other IDs
J5T-OX-JXCA, PBP-301, 2021-002641-15, 2024-515604-39-00
Acronym
SPLASH
Status last verified
Dec 2025
First submitted
23 Nov 2020
Last updated
13 Jan 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016 Jul;57(7):1006-13. doi: 10.2967/jnumed.115.168443. Epub 2016 Jan 21.

    PubMed 26795286

  • Hansen AR, Probst S, Beauregard JM, Viglianti BL, Michalski JM, Tagawa ST, Sartor O, Tutrone RF, Oz OK, Courtney KD, Delpassand ES, Nordquist LT, Osman MM, Chi KN, Sparks R, George N, Hawley SM, Wu W, Jensen JD, Fleshner NE. Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial. Front Oncol. 2025 Jan 7;14:1483953. doi: 10.3389/fonc.2024.1483953. eCollection 2024.

    PubMed 39839782

  • American College of Nuclear Medicine (ACNM) 2022 ACNM Annual Meeting AbstractsJanuary 27-29, 2022 Virtual Meeting. Clin Nucl Med. 2023 Feb 3:e246-e277. doi: 10.1097/RLU.0000000000004535. Online ahead of print. No abstract available.

    PubMed 36735603

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing [Lu-177]-PNT2002, Abiraterone and Enzalutamide in people with Metastatic Castration-Resistant Prostate Cancer, run by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company at 54 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 27 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 54 sites in United States, Canada, France, Netherlands, Sweden and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Jan 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Randomization Phase: Radiographic Progression-Free Survival (rPFS) (time frame: From the randomization date to the first documented progressive disease or death from any cause (up to 23 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04647526, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in